The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacogenetics as predictor of sunitinib and mTOR inhibitors toxicity in patients with metastatic renal cell carcinoma (mRCC).
Yuksel Urun
No relevant relationships to disclose
Kathryn P. Gray
No relevant relationships to disclose
Sabina Signoretti
No relevant relationships to disclose
David F. McDermott
No relevant relationships to disclose
Michael B. Atkins
No relevant relationships to disclose
Megan E. Lampron
No relevant relationships to disclose
Matthew Freedman
No relevant relationships to disclose
Toni K. Choueiri
No relevant relationships to disclose
Mark M Pomerantz
No relevant relationships to disclose